Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.

Abstract: A packaged semiconductor device is made by forming a conductive pad on an external surface of an integrated circuit device, forming a passivation layer over the conductive pad, removing a portion of the passivation layer over a bond area on the conductive pad, forming a sacrificial anode around a majority of a periphery surrounding the bond area, forming a conductive bond in the bond area, and forming an encapsulating material around the conductive bond and an exposed portion of the sacrificial anode.

Abstract: An upgradeable distribution framework, cable connector and cabling management system is described. The distribution framework has a plurality of ports adapted to be connected by cable connectors and indicator elements arranged on the distribution framework wherein corresponding to at least a portion of the ports. A plurality of first communication units are detachably secured to the cable connectors and such that the first communication units are positioned outside the ports when the cable connectors are inserted into the ports. The distribution framework further includes a plurality of second communication units that correspond to at least a portion of the ports. The second communication units and the corresponding first communication units are configured to communicate with each other in a non-contact manner. A control modules is configured to control and read and write communications between at least a portion of the first communication units and the second communication units.

Abstract: A patch cord, a management system and a management method thereof are provided. The patch cord (10) comprises a connection line portion (11), a first connector (21) arranged at a first end of the connection line portion (11), a second connector (22) arranged at a second end of the connection line portion (11), a first communication unit (31) arranged at near the first connector (21) including a first identifier and a second communication unit (32) arranged near the second connector (22) including a second identifier, wherein the first and second identifiers contain unique identify information for identifying the first connector and the second connector, respectively, and wherein the first identifier is different from the second identifier. The management system and the management method can differentiate connectors at the both ends of the patch cord by self-identification.

Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Abstract: The invention relates to methods and devices for measuring or monitoring a subject undergoing one or more therapeutic treatments in real time to prevent drug abuse or misuse. The devices of the invention are intended to be worn or carried by the subjects, and they can thus be defined as portable or wearable devices. The devices are further configured to monitor the subjects and to prevent potential drug abuse or drug overdose.

Abstract: The invention relates to methods and devices for measuring or monitoring a subject undergoing one or more therapeutic treatments in real time to prevent drug abuse or misuse. The devices of the invention are intended to be worn or carried by the subjects, and they can thus be defined as portable or wearable devices. The devices are further configured to monitor the subjects and to prevent potential drug abuse or drug overdose.

Abstract: A solar cell comprising a semiconductor substrate, an intrinsic semiconductor layer, a second conductive type semiconductor layer, a transparent conductive layer, a metal electrode, a light reflective unit, and a transparent packaging layer. The semiconductor substrate has an illuminated surface, which includes an effective absorption region and an ineffective absorption region. The intrinsic semiconductor layer is formed on the illuminated layer. The second conductive type semiconductor layer is formed on the intrinsic semiconductor layer. The transparent conductive layer is formed on the second conductive type semiconductor layer. The metal electrode is located on the transparent conductive layer. The light reflective unit is located on the ineffective absorption region and has a first inclined reflective surface. The transparent packaging layer is located on the transparent conductive layer, the metal electrode, and the light reflective unit.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: A patch cord, a management system and a management method thereof are provided. The patch cord (10) comprises a connection line portion (11), a first connector (21) arranged at a first end of the connection line portion (11), a second connector (22) arranged at a second end of the connection line portion (11), a first communication unit (31) arranged at near the first connector (21) including a first identifier and a second communication unit (32) arranged near the second connector (22) including a second identifier, wherein the first and second identifiers contain unique identify information for identifying the first connector and the second connector, respectively, and wherein the first identifier is different from the second identifier. The management system and the management method can differentiate connectors at the both ends of the patch cord by self-identification.

Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Abstract: An upgradeable distribution framework, cable connector and cabling management system is described. The distribution framework has a plurality of ports adapted to be connected by cable connectors and indicator elements arranged on the distribution framework wherein corresponding to at least a portion of the ports. A plurality of first communication units are detachably secured to the cable connectors and such that the first communication units are positioned outside the ports when the cable connectors are inserted into the ports. The distribution framework further includes a plurality of second communication units that correspond to at least a portion of the ports. The second communication units and the corresponding first communication units are configured to communicate with each other in a non-contact manner. A control modules is configured to control and read and write communications between at least a portion of the first communication units and the second communication units.

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

Abstract: A packaged semiconductor device is made by forming a conductive pad on an external surface of an integrated circuit device, forming a passivation layer over the conductive pad, removing a portion of the passivation layer over a bond area on the conductive pad, forming a sacrificial anode around a majority of a periphery surrounding the bond area, forming a conductive bond in the bond area, and forming an encapsulating material around the conductive bond and an exposed portion of the sacrificial anode.

Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.